The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2018 | Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including T-cell therapies and bispecific antibodies. Here, our expert panel discuss BCMA and SLAMF7 targeting CAR T-cells, bispecific T-cell engaging antibodies, and recent clinical trials in these areas. From the Myeloma 2018 meeting in San Diego, CA, Andrzej Jakubowiak, MD, PhD, from the University of Chicago Medical Center, Chicago, IL chairs a discussion with James Kochenderfer, MD, of the National Cancer Institute, Bethesda, MD, and Adam Cohen, MD, of the University of Pennsylvania, Philadelphia, PA.
